Minomic Launches U.S. Study of MiCheck Prostate Cancer Screening Test

Minomic Launches U.S. Study of MiCheck Prostate Cancer Screening Test
Minomic International, an Australian immuno-oncology company, has initiated a prospective trial of its MiCheck Prostate Cancer Screening Test in the United States to further verify the technology’s accuracy and reliability in detecting prostate cancer. MiCheck works by analyzing a patient's blood sample to detect the presence of prostate cancer. For this trial, 50 healthy control patients and 300 patients planning to undergo prostate biopsy will be analyzed with MiCheck. An uro-oncology trials group, CUSP, will oversee the sample collection from 10 or more urology practices in the United States. “Advancing biomarker technology to assist both patients and physicians in order to optimize a shared-decision making regarding a choice to have a prostate biopsy, or not, is both clinically important for patient outcomes and also for enhancing value based healthcare goals," Neal D. Shore, MD, FACS, medical director at the Carolina Urologic Research Center, said in a press release. Shore is conducting the trial, after leading more than 300 clinical studies related to prostate cancer. "Thus we are looking forward to this important trial which will augment our earlier findings presented at AUA, New Orleans, 2015,” he added, referring to a previous American Urological Association annual meeting. The MiCheck test works by screening a biomarker, known as the MIL-38 antigen, which is found at the surface of prostate cancer cells. In prior trials, the test demonstrated a specificity of 85 percent, which contrasts with the 40 percent specific
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *